Tuesday, January 25, 2022 at 4pm EST Wednesday, January 26, 2022 at 6am JST Join IQVIA Biotech to gain insights into the key milestones on the roadmap to commercial success in Japan
Register Free: http://www.pharmexec.com/pe_w/market_entry
Commercial success in Japan, the 2nd largest branded pharmaceutical market, requires an understanding of key pathways to approval and launch, and a clearly defined go-to-market strategy.
Join IQVIA Biotech to gain insights into the key milestones on the roadmap to commercial success in Japan.
3 Key take-aways
Pathways to approval
Market entry strategies
Building a commercial presence
For any technical questions, please contact Julia Longo, firstname.lastname@example.org
Director, Thought Leadership
IQVIA Japan Group
Alan Thomas brings over 20 years of experience in healthcare consulting and services, 7 of which as head of the IQVIA Japan Thought Leadership team. He works with multiple stakeholders within healthcare, delivering data-driven intelligence and decision support including clinical and commercial insights, dynamics within the Japan and global markets, and impact of policy and trends on the future outlook of healthcare. He holds a Bachelor’s degree in Economics and Marketing from the Swinburne Institute in Australia.
Barry O’Connor, Ph.D
Associate Director, Customer Alliance
IQVIA Japan Group
Barry leads the Molecule to Market efforts for IQVIA Biotech in Japan supporting Biotech in their pursuit of approval of their assets and entry to the Japanese market. Barry has been working in the healthcare industry in Japan for 10 years and has been with IQVIA since 2017. He holds a Chemistry degree from Trinity College Dublin, Ireland and PhD from the University of Manchester, UK
Register Free http://www.pharmexec.com/pe_w/market_entry